Background:  IGF2BP2 (insulin-like growth factor 2 mRNA binding protein 2) is also known as IGF2 mRNA-binding protein 2, IMP-2 (IGF-II mRNA-binding protein 2), VICKZ family member 2 or hepatocellular carcinoma autoantigen p62 and is a 556 amino acid protein. IGF2BP2 is expressed in a variety of tissues including heart, placenta, skeletal muscle, pancreas, fetal liver, lung, kidney, thymus and gonadal cells. IGF2BP2 is an RNA binding protein which may be involved in the regulation of mRNA translation and may also function to control the spatial localization of target mRNAs. Antibodies against IGF2BP2 have been detected in patients with HCC (hepatocellular carcinoma), suggesting that IGF2BP2 may have a role in the pathogenesis of HCC. Defects in IGF2BP2 are thought to be associated with susceptibility to type 2 diabetes mellitus.

Description: Rabbit polyclonal to IGF2BP2

Immunogen: KLH conjugated synthetic peptide derived from IGF2BP2

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 66 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.